Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;26(5):293-301.
doi: 10.2165/00002018-200326050-00001.

Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions

Affiliations

Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions

Eugène van Puijenbroek et al. Drug Saf. 2003.

Abstract

The primary aim of spontaneous reporting systems (SRSs) is the timely detection of unknown adverse drug reactions (ADRs), or signal detection. Generally this is carried out by a systematic manual review of every report sent to an SRS. Statistical analysis of the data sets of an SRS, or quantitative signal detection, can provide additional information concerning a possible relationship between a drug and an ADR. We describe the role of quantitative signal detection and the way it is applied at the Netherlands Pharmacovigilance Centre Lareb. Results of the statistical analysis are implemented in the traditional case-by-case analysis. In addition, for data-mining purposes, a list of associations of ADRs and suspected drugs that are disproportionally present in the database is periodically generated. Finally, quantitative signal generation can be used to study more complex relationships, such as drug-drug interactions and syndromes. The results of quantitative signal detection should be considered as an additional source of information, complementary to the traditional analysis. Techniques for the detection of drug interactions and syndromes offer a new challenge for pharmacovigilance in the near future.

PubMed Disclaimer

References

    1. Br J Clin Pharmacol. 1997 Nov;44(5):513-8 - PubMed
    1. Eur J Clin Pharmacol. 1998 Jun;54(4):315-21 - PubMed
    1. Drug Saf. 2002;25(6):453-8 - PubMed
    1. Stat Med. 2000 Dec 15;19(23 ):3199-209 - PubMed
    1. Stat Med. 1982 Apr-Jun;1(2):153-61 - PubMed

MeSH terms

LinkOut - more resources